2. Academic Validation
  3. Enibarcimab for the treatment of septic shock in patients selected by a combination of the biomarkers bio-ADM and DPP3: A prespecified subgroup analysis of the AdrenOSS-2 trial

Enibarcimab for the treatment of septic shock in patients selected by a combination of the biomarkers bio-ADM and DPP3: A prespecified subgroup analysis of the AdrenOSS-2 trial

  • J Crit Care. 2025 Aug:88:155077. doi: 10.1016/j.jcrc.2025.155077.
Claudia Knothe 1,  Stephan Witte 1,  Andreas Bergmann 2,  Alexandre Mebazaa 3,  Pierre-Francois Laterre 4,  Peter Pickkers 5,  ADRENOSS-2 Investigators
Affiliations

Affiliations

  • 1 Adrenomed AG, Neuendorfstr. 15a, 16761 Hennigsdorf, Germany.
  • 2 4Teen4, Neuendorfstrasse 15A, 16761 Hennigsdorf, Germany.
  • 3 Département d'Anesthésie-Réanimation, Hôpital Lariboisière, 2 Rue A Paré, 75010 Paris, France.
  • 4 Cliniques Universitaires Saint-Luc, (UCL Bruxelles), Avenue Hippocrate 10, 1200 Brussels, Belgium.
  • 5 Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands. Electronic address: [email protected].
PMID: 40215573 DOI: 10.1016/j.jcrc.2025.155077
Figures
Products